Advertisement
open access
Medical Conferences

Medical Conferences

  • Conference Reports
    • 2023 Medicom Conference Planning
  • Conference Proceedings
  • Disease Areas
  • Other Medical News
  • Media
    • Podcast
    • Video
    • Education
  • About
    • Conference Proceedings
    • Vacancies

Tag: Galcanezumab

Over a third of patients responds late to CGRP antibodies

Presented By
Dr Cinzia Aurilia, University of Florence, Italy
Conference
EAN 2022

22 August, 2022 14:59

Galcanezumab effective in patients with episodic or chronic cluster headache

Presented By
Dr Charly Gaul, Headache Clinic Königstein, Germany
Trial
Phase 3
Conference
IHC 2021

8 November, 2021 16:04

Central effects and affected somatosensory processing with galcanezumab in migraine

Presented By
Dr Hauke Basedau, Dr Kuan-Po Peng, University Medical Centre Hamburg-Eppendorf, Germany
Conference
IHC 2021

8 November, 2021 16:00

CGRP antagonists and complications in patients with Raynaud’s phenomenon

Conference
AAN 2021

16 June, 2021 11:49

Less medication use and fewer doctor visits with galcanezumab in treatment-resistant migraine

Presented By
Prof. Julio P. Gómez, Hospital Universitario Marqués de Valdecilla, Spain
Trial
Phase 3, CONQUER
Conference
MTIS 2020

27 October, 2020 15:16

Sustained shift in migraine status using galcanezumab

Presented By
Dr William S. Kingston, Sunnybrook Health Sciences Centre, Canada
Trial
Phase 3, CONQUER
Conference
MTIS 2020

27 October, 2020 14:35

Injection-site reactions with galcanezumab are mild and self-limiting

Presented By
Dr V.L. Stauffer
Trial
Phase 3, CONQUER
Conference
MTIS 2020

27 October, 2020 14:27

Effects of galcanezumab on health-related quality of life

Presented By
Dr Stewart Tepper, Geisel School of Medicine, USA
Trial
Phase 3, CONQUER
Conference
EAN 2020

9 September, 2020 16:44

Galcanezumab reduces healthcare resource utilisation

Trial
Phase 3, REGAIN
Conference
EAN 2019

27 August, 2019 19:17
site created by:   

© 2023 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy